'Wild speculations': BeiGene hits back at short seller's accusations of 60% sales inflation

9th September 2019 Uncategorised 0

BeiGene leapfrogged onto the commercial stage thanks to its acquisition of Celgene’s Chinese operations. But now, those very assets have attracted some serious allegations as a New York investment shop accuses the firm of inflating its sales by 60%.

More: 'Wild speculations': BeiGene hits back at short seller's accusations of 60% sales inflation
Source: fierce